October 17, 2019 will mark the expansion of the cannabis regulations in Canada allowing for concentrates, vapes and an expanded range of formulated medical products. EnCann expects to receive its Standard Processor License in Q4 2019 and is poised to take advantage of the coming increase in extraction demand. 

Every aspect of EnCann’s oil production is subject to Health Canada’s regulations and monitoring requiring quality testing in a controlled environment: a clean and secure pharmaceutical grade facility where all products are carefully tracked. 

EnCann’s extraction process is a proprietary, patent-pending system which will revolutionize the industry. By employing the newest technologies, EnCann is able to process cannabis and industrial hemp biomass at industrial scale, all while maintaining a top-quality product. The company is focused on creating custom THC, CBD and terpene blends that are specifically tailored to the requirements of their customers: cannabis producers, product manufacturers, researchers, retailers and exporters licensed to deal in cannabis products.  

As consumers become more educated, providing an expanded product range including capsules, topicals, unique oral release profiles and nanoemulsions will become key for Standard and Micro Cultivators to remain competitive and to maintain their profit margins. Through our future planned white labelling services, EnCann will allow cultivators to provide an expanded product line.

At this time, we are looking for investors to help us to advance our vision of transforming the global cannabis industry. EnCann offers a unique opportunity to invest in a market which is seeing unprecedented growth and profits, a privately held company focused on creating profit and in an established team of cannabis industry experts. 

For more information or investment inquiries, please email or call Darcy Dando, CFO, or see our Investors Presentation below:

Investor Presentation